Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

Methods of Documentation V: CBE

Methods of Documentation V: CBE

Charting by Exception, or CBE, is a method of documentation used in healthcare, particularly in nursing, that focuses on documenting only significant or abnormal findings rather than recording every detail. This approach aims to streamline the documentation process, improve efficiency, and ensure that healthcare providers can quickly identify deviations from normalcy in patient assessments.
In CBE, healthcare professionals establish predefined standards of practice that define what constitutes...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Analgesic efficacy in women and men with cancer pain, treated with strong opioids: are there differences?

BMJ oncology·2026

Same author

CardioPulmonary resuscitation with <i>Ar</i>gon (CP<i>Ar)</i>: A protocol for a randomised controlled multicentre clinical trial.

Resuscitation plus·2025

Same author

[New European Pharmaceutical Legislation: a challenge to reconcile public health protection and market competitiveness].

Epidemiologia e prevenzione·2025

Same author

Do Not Let the Guard Down on Preventable Behavioral Risk Factors.

Journal of epidemiology·2025

Same author

[NNT and NNH: statistics and stochastics in the evaluation of added therapeutic value].

Giornale italiano di cardiologia (2006)·2024

Same author

An Italian Consensus Conference on Psychological Therapies for Anxiety and Depression.

Clinical neuropsychiatry·2024

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

Evaluation of benefit-risk.

Silvio Garattini¹

¹Mario Negri Institute for Pharmacological Research, Milan, Italy. silvio.garattini@marionegri.it

Pharmacoeconomics

|August 5, 2010

Summary

Assessing drug benefit-risk balance is challenging due to measurement limitations for both benefits and risks. Pharmacoeconomics, using quality-adjusted life years (QALYs), offers potential solutions but requires further development for individual-level prediction.

Area of Science:

Pharmacology
Health Economics
Clinical Decision-Making

Background:

Drug authorization, prescription, and utilization rely on benefit-risk assessment.
Objective measurement of drug benefits and risks presents significant challenges.
Existing methods struggle with individual-level prediction and comparing disparate outcomes.

Purpose of the Study:

To explore the complexities and limitations in current benefit-risk assessment methodologies for drugs.
To evaluate the potential of pharmacoeconomic tools, such as Quality-Adjusted Life Years (QALYs), in improving benefit-risk evaluations.
To identify gaps in research and application for utilizing health outcomes modeling in clinical practice.

Main Methods:

Review of current practices in drug benefit-risk assessment.

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Related Experiment Videos

Last Updated: Jun 10, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Exploration of pharmacoeconomic modeling, specifically QALYs, for health outcomes.

Analysis of limitations in clinical studies regarding quality of life and safety data.

Main Results:

Benefit-risk assessment is hampered by surrogate benefit indicators and unpredictable, delayed risks.
The benefit-risk balance lacks standardized measurement, complicating comparisons across diseases and patient groups.
QALYs offer a framework for integrating survival and quality of life but face challenges in consistent assessment and individual prediction.

Conclusions:

Current benefit-risk assessment methods are insufficient for precise individual patient decision-making.
Pharmacoeconomics provides valuable tools for evaluating treatment value and trade-offs, but requires further refinement.
Improved methods for assessing quality of life and developing predictive QALY models are crucial for advancing clinical utility.